Who
Anne McGeorge
Director
Company insider
Files Form 4 as: Director, Dianthus Therapeutics; Director, The Oncology Institute; Director and Other, SOC Telemed.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $1.7M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 20 Jun 2019
- Last trade
- 10 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K1,250 at $19.36 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $73K6,500 at $11.20 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $156K1,450 at $107.58 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,500 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $303K2,800 at $108.38 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $197K1,800 at $109.30 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K1,000 at $110.64 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K700 at $111.41 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,500 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K1,250 at $19.36 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $73K6,500 at $11.20 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $156K1,450 at $107.58 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $303K2,800 at $108.38 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $197K1,800 at $109.30 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K1,000 at $110.64 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K700 at $111.41 | filing |
| 27 Jul 2026filed 29 Jul 2026 | The Oncology InstituteProviders & Facilities | SEC FORM 4 Code A | —41,165 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | The Oncology InstituteProviders & Facilities | SEC FORM 4 Code A | —41,165 at $0.00 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Anne McGeorge; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.